Navigation Links
Ampio Awarded US and Canadian Patents that will Bolster the Commercialization of Optina™ for the treatment of Diabetic Macular Edema (DME)
Date:4/27/2012

e eyes is often an early form of diabetic retinopathy that causes significant vision loss.  Almost all Type 1 diabetics and more than 60% of Type 2 diabetics will develop retinopathy. There is no effective daily drug treatment for diabetic retinopathy other than general measures, such as controlling blood sugar, hypertension, blood lipids, etc. Due to the global diabetes epidemic, diabetic retinopathy is recognized as a high, unmet medical need that would benefit from having oral therapeutic options available. The only treatments available for macular edema now are laser therapy, injection or implantation of drugs into or around the eyeball (not approved in the US or Canada). To our knowledge, Optina™ is the only proposed oral treatment for this condition.

About Optina™
Optina™ is an orally administered ultra low dose of danazol, for the treatment of diabetic macular edema (DME).  Ampio's Chief Scientific Officer discovered an unexpected activity in his investigation of the mechanism of action of danazol: very low doses reversed inflammation-induced increases in the permeability of blood vessels, thus reducing vascular leakage.  Dr. Bar-Or subsequently managed in-vitro studies that suggested this effect may reduce the vasogenic edema produced by various vascular leak syndromes, including diabetic macular edema (DME) which can impair vision and cause blindness. The specific Optina dosages used in the trial are proprietary and subject to multiple patent filings.

Danazol, a derivative of the synthetic steroid ethisterone, was approved by the FDA in the 1970s for endometriosis and, more recently, for other chronic indications, including hereditary angioedema, ITP and fibrocystic disease of the breast.

About Ampio
Ampio Pharmaceuticals, Inc. develops innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfun
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Strengthens Patent Protection for Lead Drug Ampion™
2. Ampio Announces Positive Preliminary Update on the Optina™ Clinical Trial to Treat Diabetic Macular Edema and Decision to Conclude the Study Ahead of Schedule
3. Champions Oncology Reports Fiscal 2012 Third Quarter Financial Results
4. Ampio Pharmaceuticals Reports Full-Year 2011 Financial Results and Milestone Highlights for 2011
5. Ampio Pharmaceuticals Schedules 2012 Outlook Webcast
6. Executive Changes at Ampio
7. Ampio Pharmaceuticals Schedules Webcast to Update Shareholders
8. Ampio Pharmaceuticals Announces Registered Direct Common Stock Offering of Approximately $9.436 Million
9. Ampio Responds to Recent Publications by Anonymous Short Sellers
10. Champions Oncology Reports Fiscal 2012 Second Quarter Financial Results
11. FDA Advisory Panel Recommends Against Approval of Champion® Heart Failure Management System for Patients With Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... ANGELES , July 24, 2014  Bruin ... devices, announced today that after two weeks of ... throughout the European Union, it gained substantial concurrence ... moisture) and the clinical utility of BBI,s SEM ... over 90 percent of the respondents drawn from ...
(Date:7/24/2014)... Quebec , July 24, 2014 ... VRX ) (TSX:VRX) announced today that it has ... marches financiers ("AMF") regarding Allergan, Inc.,s (NYSE: ... and to negatively influence the market price of ... and misleading statements regarding Valeant,s business despite Valeant,s ...
(Date:7/24/2014)... , July 24, 2014  Xencor, Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... will release second quarter financial results after market close ... a webcast and conference call the same day at ... financial results and provide a corporate update. ...
Breaking Medicine Technology:Bruin Biometrics Secures Support of EU Scientific Community for its SEM Scanner Technology 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 2Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 3Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 4Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 5Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements 6Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 2
... Dec. 14, 2010 Biodel Inc. (Nasdaq: BIOD ... the company,s Chief Scientific Officer.  Dr. Steiner is a co-founder ... board of directors.  He served as Biodel,s chairman, president and ... March 2010 when Dr. Errol De Souza was named the ...
... announces that a new market research report is ... Pharmaceuticals Research Review http://www.reportlinker.com/p0341171/2010-Pharmaceuticals-Research-Review.html ... has accentuated the fault lines already dividing the ... pharma companies, coupled with the patent expiration precipice, ...
Cached Medicine Technology:Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 2Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 3Biodel Announces Retirement of Dr. Solomon Steiner as Chief Scientific Officer 4Reportlinker Adds 2010 Pharmaceuticals Research Review 2Reportlinker Adds 2010 Pharmaceuticals Research Review 3Reportlinker Adds 2010 Pharmaceuticals Research Review 4Reportlinker Adds 2010 Pharmaceuticals Research Review 5Reportlinker Adds 2010 Pharmaceuticals Research Review 6Reportlinker Adds 2010 Pharmaceuticals Research Review 7Reportlinker Adds 2010 Pharmaceuticals Research Review 8Reportlinker Adds 2010 Pharmaceuticals Research Review 9Reportlinker Adds 2010 Pharmaceuticals Research Review 10Reportlinker Adds 2010 Pharmaceuticals Research Review 11Reportlinker Adds 2010 Pharmaceuticals Research Review 12Reportlinker Adds 2010 Pharmaceuticals Research Review 13Reportlinker Adds 2010 Pharmaceuticals Research Review 14
(Date:7/24/2014)... (PRWEB) July 24, 2014 Becker's Hospital ... "100 Hospitals and Health Systems With Great Oncology Programs." ... in terms of quality patient care, cancer outcomes and ... hospitals for inclusion based on rankings and awards they ... following awards were considered as part of the criteria ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 The European Omega ... omega 3 & structured lipids market in Europe with analysis ... from around $670.37 million in 2012 to $989.91 million by ... , Browse through the TOC of the European omega 3 ... the in-depth analysis provided. This also provides a glimpse of ...
(Date:7/24/2014)... 24, 2014 The European air and missile ... 2014, and is expected to register a CAGR of 8.06%, ... Russia, and turkey are the major spenders in the region ... extended air defense program and multinational (MEADS) program, which has ... through the TOC of the Europe air and missile defense ...
(Date:7/24/2014)... p53 refers to cancer biology, and the functions of ... in detail. Furthermore, also in cancer biology, it is ... cells in order to block their metabolism and prevent ... research on p53 attempts to unveil its functions in ... cells. Recent studies with cell cultures have demonstrated that ...
(Date:7/24/2014)... malaria parasite becomes resistant to an investigational drug. ... in St. Louis, also is relevant for other ... The study appears July 24 in Nature ... that causes malaria, make a class of molecules ... organisms healthy, whether plants, animals or bacteria. In ...
Breaking Medicine News(10 mins):Health News:100 Hospitals, Health Systems With Great Oncology Programs 2Health News:100 Hospitals, Health Systems With Great Oncology Programs 3Health News:100 Hospitals, Health Systems With Great Oncology Programs 4Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Omega 3 & Structured Lipids (Nutraceuticals) Market is Expected to Reach $989.91 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 2Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 3Health News:Europe Air and Missile Defense Radar Market is Expected to Reach $2.07 billion in 2020 - New Report by MicroMarket Monitor 4Health News:Identified a key molecule in flies that adjusts energy use under starvation conditions 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3
... University of Alabama at Birmingham (UAB) this month became ... cancer radiation therapy. The new technique can turn a ... patients. , Additionally, the new therapy saves healthy human ... the same or better than other radiotherapy techniques, according ...
... MEDI3) (MEDIAL SAUDE) announces the following webcast:, What: Medial Saude ... 2008 @ 12:00 PM EDT, Where: http://prnewswire.isat.com.br/?palestra_id=305 , How: ... the address above., ... Toll-free from the US: (1 800) 860-2442; ...
... might be swaying clinicians , , WEDNESDAY, May ... overdiagnosed, say researchers at Rhode Island Hospital and ... half of patients previously diagnosed with bipolar disorder ... -- the Structured Clinical Interview for DSM-IV (SCID). ...
... Shire plc (LSE: SHP, NASDAQ: SHPGY), the global ... new data analysis that was conducted to examine ... boys and girls aged 6 to 12 years ... findings from the analysis reaffirmed that DAYTRANA has ...
... Agrees to $2.3 million fine, CARMEL, Ind., ... ),today announced a settlement among state insurance regulators ... Insurance (CSHI) Company,and Bankers Life and Casualty Company. ... by Pennsylvania, Illinois,Indiana, Texas and Florida related to ...
... Vail Valley ... Medical Center, VAIL, Colo., May ... today the appointment of the new President,and CEO, John H. Cassin. Cassin ... Medical Center., "John brings great leadership experience and an engaging personal,style, ...
Cached Medicine News:Health News:UAB first in US to offer speedier precise cancer radiotherapy 2Health News:Bipolar Disorder Might Be Overdiagnosed 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 2Health News:New analysis shows DAYTRANA offered ADHD symptom control for 12 months 3Health News:Conseco Reaches Settlement of Multistate Market Conduct Examination 2Health News:Vail Valley Medical Center Board of Directors Announces Appointment of New President & CEO, John Cassin 2
Karlin XL Magnum Ring Curettes, extra long (XL) curettes, black handles, lightweight. Length 13 1/4" (33.7 cm), handle length 8 1/2" (21 cm), handle diameter 1 1/4" (32 cm)....
Hardy Curettes, bayonet, working distance 4 3/4" (120 mm), total length 9 1/2" (241 mm), tip width 3 mm....
PG Magnum Ring Curettes, total length 12.6" (32 cm), handle length 7.8" (20 cm), handle diameter 1.12" (3 cm), working distance 4.7" (12 cm), dual-coned, precision sharpened rings....
Karlin Cervical Microdiscectomy Curette, length 8 1/2" (21 cm)....
Medicine Products: